Rocket Pharmaceuticals, Inc. (RCKT) Stock Score, Valuation & Financial Research

Rocket Pharmaceuticals, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for RCKT

Rocket Pharmaceuticals, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 2.21. These figures are a research snapshot, not a buy or sell recommendation.

What Rocket Pharmaceuticals, Inc. does

Rocket Pharmaceuticals, Inc., operating alongside its affiliates, is an innovative biotechnology enterprise dedicated to pioneering gene therapies for rare and severely debilitating diseases. The company's active clinical pipeline features multiple promising programs. It is currently progressing three ex vivo lentiviral vector therapies aimed at specific genetic conditions: Fanconi anemia, characterized by a bone marrow defect that hinders blood cell production; leukocyte adhesion deficiency-I, an inherited disorder resulting in a compromised immune system; and pyruvate kinase deficiency, a rare autosomal recessive red blood cell ailment leading to chronic non-spherocytic hemolytic anemia. Complementing these, Rocket Pharmaceuticals also has an in vivo adeno-associated virus program underway for Danon disease, a serious multi-organ lysosomal storage disorder that tragically often results in early mortality due to heart failure. To facilitate its extensive research and development efforts, the company has established key licensing partnerships with esteemed institutions such as the Fred Hutchinson Cancer Research Center, European research bodies including CIEMAT and its collaborators (Centro de Investigacion Biomedica En Red and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz), UCL Business PLC (in conjunction with CIEMAT), The Regents of the University of California, and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. maintains its primary corporate location in Cranbury, New Jersey.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Rocket Pharmaceuticals is a clinical-stage biotechnology company focused on developing gene therapies for rare, devastating diseases. As a pre-commercial entity, the company does not currently generate revenue from product sales and relies on capital raises and strategic collaborations to fund its extensive research and development activities.

Products and services

  • The company's pipeline includes gene therapy candidates utilizing lentiviral and adeno-associated viral vectors, targeting conditions such as Danon disease, Fanconi anemia, and Leukocyte Adhesion Deficiency-I.

Customer types

Healthcare providers and clinical research institutions.

Suppliers, materials and equipment

  • Contract Manufacturing Organizations — The company relies on third-party contract manufacturing organizations for the production of clinical trial materials and viral vectors; specific supplier names are not disclosed. Source

Competitors and product-market comparisons

  • Gene therapy and biotechnology companies — The company competes with various pharmaceutical and biotechnology firms developing gene-based therapies for rare genetic disorders. Source

Business strengths to evaluate

  • Proprietary gene therapy platform technology Source
  • Experienced management team in rare disease drug development Source

Business risks and research considerations

  • History of operating losses and expectation of future losses Source
  • Dependence on successful clinical trial outcomes and regulatory approvals Source
  • Reliance on third-party manufacturers for clinical supply Source

Sources: Company research source

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

RCKT financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 2.21
Market capitalization:
242.6M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -17.25M
Free cash flow:
USD -190.45M
Cash:
USD 224.51M
Total debt:
USD 24.8M
EPS:
USD -0.16

What stands out

  • Free cash flow is USD -190.45M, negative for the stored period.
  • The balance sheet shows USD 224.51M of cash versus USD 24.8M of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a missing revenue history warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 199.71M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for RCKT

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can RCKT fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is RCKT likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for RCKT to reach sustainable profitability?
  • What does the current missing revenue history warning mean for the reliability or interpretation of RCKT's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-15.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research RCKT

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.